Reuters reported exclusively how Shionogi, Japan’s most profitable drugmaker by operating margin, is being prodded into seizing more sales for itself instead of relying on bigger partners, as a key HIV drug and three combination medicines will open to generic competition in nine years time. The company plans to develop its own U.S. sales team for cefiderocol, an antibiotic it hopes will gain approval this year and which will be used as a last-resort treatment for patients with infectious disease not cured by other antibiotics, CEO Isao Teshirogi told Reuters in an interview.
Reuters reveals Shionogi moves to develop its own U.S. sales staff
16 July 2019, 12:00 am 1 minute
Type: Reuters Best
More of Reuters Best
September 04, 2023
August 28, 2023